NCT00085189 - Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Ciliary Body and Choroid Melanoma, Medium/Large SizeCiliary Body and Choroid Melanoma, Small SizeExtraocular Extension MelanomaIris MelanomaMetastatic Intraocular MelanomaMucosal MelanomaRecurrent Intraocular MelanomaRecurrent MelanomaStage IIC MelanomaStage IIIA Intraocular MelanomaStage IIIA MelanomaStage IIIB Intraocular MelanomaStage IIIB MelanomaStage IIIC Intraocular MelanomaStage IIIC MelanomaStage IV Intraocular MelanomaStage IV Melanoma

Interventions

BIOLOGICAL

gp100 antigen

Given SC

BIOLOGICAL

tyrosinase peptide

Given SC

BIOLOGICAL

recombinant MAGE-3.1 antigen

Given SC

BIOLOGICAL

multi-epitope melanoma peptide vaccine

Given SC

BIOLOGICAL

incomplete Freund's adjuvant

Given SC

DRUG

Montanide ISA 51 VG

Given SC

DRUG

agatolimod sodium

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

90033-0804

University of Southern California, Los Angeles

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER